Veronica F Quinn1, Bettina Meiser1, Judy Kirk2,3, Kathy M Tucker4, Kaaren J Watts1, Belinda Rahman1, Michelle Peate1,5, Christobel Saunders6, Elizabeth Geelhoed7, Margaret Gleeson8, Kristine Barlow-Stewart9, Michael Field10, Marion Harris11, Yoland C Antill11,12, Linda Cicciarelli13, Karen Crowe14, Michael T Bowen15, Gillian Mitchell13,16. 1. Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Sydney, Australia. 2. Familial Cancer Service, Westmead Hospital, Westmead, Australia. 3. Centre for Cancer Research, The Westmead Institute for Medical Research, University of Sydney, Westmead, Australia. 4. Department of Medical Oncology, Hereditary Cancer Clinic, Prince of Wales Hospital, Randwick, Australia. 5. Department of Obstetrics & Gynaecology, Royal Women's Hospital, University of Melbourne, Parkville, Australia. 6. School of Surgery, University of Western Australia, Crawley, Australia. 7. School of Population Health, University of Western Australia, Crawley, Australia. 8. Hunter Family Cancer Service, Waratah, Australia. 9. Sydney Medical School-Northern, University of Sydney, Sydney, Australia. 10. Royal North Shore Hospital, St Leonards, Australia. 11. Monash Health, Melbourne, Australia. 12. Familial Cancer Centre, Cabrini Health, Melbourne, Australia. 13. Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, Australia. 14. Genetic Health Queensland, Nambour General Hospital, Queensland, Australia. 15. School of Psychology, University of Sydney, Sydney, Australia. 16. Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Abstract
PURPOSE: Increasingly, women newly diagnosed with breast cancer are being offered treatment-focused genetic testing (TFGT). As the demand for TFGT increases, streamlined methods of genetic education are needed. METHODS: In this noninferiority trial, women aged <50 years with either a strong family history (FH+) or other features suggestive of a germ-line mutation (FH-) were randomized before definitive breast cancer surgery to receive TFGT education either as brief written materials (intervention group (IG)) or during a genetic counseling session at a familial cancer clinic (usual-care group (UCG)). Women completed self-report questionnaires at four time points over 12 months. RESULTS: A total of 135 women were included in the analysis, all of whom opted for TFGT. Decisional conflict about TFGT choice (primary outcome) was not inferior in the IG compared with the UCG (noninferiority margin of -10; mean difference = 2.45; 95% confidence interval -2.87-7.76; P = 0.36). Costs per woman counseled in the IG were significantly lower (AUD$89) compared with the UCG (AUD$173; t(115) = 6.02; P < 0.001). CONCLUSION: A streamlined model of educating women newly diagnosed with breast cancer about TFGT seems to be a cost-effective way of delivering education while ensuring that women feel informed and supported in their decision making, thus freeing resources for other women to access TFGT.Genet Med 19 4, 448-456.
PURPOSE: Increasingly, women newly diagnosed with breast cancer are being offered treatment-focused genetic testing (TFGT). As the demand for TFGT increases, streamlined methods of genetic education are needed. METHODS: In this noninferiority trial, women aged <50 years with either a strong family history (FH+) or other features suggestive of a germ-line mutation (FH-) were randomized before definitive breast cancer surgery to receive TFGT education either as brief written materials (intervention group (IG)) or during a genetic counseling session at a familial cancer clinic (usual-care group (UCG)). Women completed self-report questionnaires at four time points over 12 months. RESULTS: A total of 135 women were included in the analysis, all of whom opted for TFGT. Decisional conflict about TFGT choice (primary outcome) was not inferior in the IG compared with the UCG (noninferiority margin of -10; mean difference = 2.45; 95% confidence interval -2.87-7.76; P = 0.36). Costs per woman counseled in the IG were significantly lower (AUD$89) compared with the UCG (AUD$173; t(115) = 6.02; P < 0.001). CONCLUSION: A streamlined model of educating women newly diagnosed with breast cancer about TFGT seems to be a cost-effective way of delivering education while ensuring that women feel informed and supported in their decision making, thus freeing resources for other women to access TFGT.Genet Med 19 4, 448-456.
Authors: Sungmin Park; Jeong Eon Lee; Jai Min Ryu; Issac Kim; Soo Youn Bae; Se Kyung Lee; Jonghan Yu; Seok Won Kim; Seok Jin Nam Journal: World J Surg Date: 2018-05 Impact factor: 3.352
Authors: Janet Jull; Sascha Köpke; Maureen Smith; Meg Carley; Jeanette Finderup; Anne C Rahn; Laura Boland; Sandra Dunn; Andrew A Dwyer; Jürgen Kasper; Simone Maria Kienlin; France Légaré; Krystina B Lewis; Anne Lyddiatt; Claudia Rutherford; Junqiang Zhao; Tamara Rader; Ian D Graham; Dawn Stacey Journal: Cochrane Database Syst Rev Date: 2021-11-08
Authors: Marc D Schwartz; Beth N Peshkin; Claudine Isaacs; Shawna Willey; Heiddis B Valdimarsdottir; Rachel Nusbaum; Gillian Hooker; Suzanne O'Neill; Lina Jandorf; Scott P Kelly; Jessica Heinzmann; Aliza Zidell; Katia Khoury Journal: Breast Cancer Res Treat Date: 2018-04-02 Impact factor: 4.872
Authors: Jeanna M McCuaig; Emily Thain; Janet Malcolmson; Sareh Keshavarzi; Susan Randall Armel; Raymond H Kim Journal: Curr Oncol Date: 2021-04-08 Impact factor: 3.677
Authors: Kelly E Ormond; Mercy Ygoña Laurino; Kristine Barlow-Stewart; Tina-Marié Wessels; Shelley Macaulay; Jehannine Austin; Anna Middleton Journal: Am J Med Genet C Semin Med Genet Date: 2018-03-25 Impact factor: 3.908
Authors: Jeanna M McCuaig; Susan Randall Armel; Melanie Care; Alexandra Volenik; Raymond H Kim; Kelly A Metcalfe Journal: Cancers (Basel) Date: 2018-11-13 Impact factor: 6.639
Authors: Sarah Wright; Mary Porteous; Diane Stirling; Julia Lawton; Oliver Young; Charlie Gourley; Nina Hallowell Journal: J Genet Couns Date: 2018-05-11 Impact factor: 2.537
Authors: Martin P Nilsson; Therese Törngren; Karin Henriksson; Ulf Kristoffersson; Anders Kvist; Barbro Silfverberg; Åke Borg; Niklas Loman Journal: Breast Cancer Res Treat Date: 2017-11-21 Impact factor: 4.872